The U.S. Food and Drug Administration (FDA) has approved Medtronic’s MiniMed® 670G system, the first Hybrid Closed Loop insulin delivery system in the world, according to a release from the company. “This significant milestone represents an important step forward in the management of type 1 diabetes and will improve the quality of life for those living with...
In a statement from Janssen Pharmaceuticals, Inc. today, the company announced that the U.S. Food and Drug Administration (FDA) has approved INVOKAMET® XR — a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR) — for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with...
Simple changes in how we cook could go a long way towards preventing diabetes, say researchers at the Icahn School of Medicine at Mount Sinai. A new randomized controlled trial, published online July 29 in the journal Diabetologia, found that obese individuals with signs of insulin resistance showed improvement simply by avoiding the intake of...
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on biologic insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. This new follow-on biologic is being developed by Merck with partial funding from Samsung Bioepis. A follow-on biologic...
The National Diabetes & Obesity Research Institute (NDORI) today in Mississippi announced an affiliation with the Cleveland Clinic Endocrinology & Metabolism Institute designed to enhance diabetes- and obesity-related research, discover better treatment protocols, and, ultimately, cultivate a healthier Mississippi and nation. The affiliation combines the academic, clinical and research components of the Cleveland Clinic Endocrinology & Metabolism...
Caladrius Biosciences, Inc., announced today that its product candidate CLBS03 (autologous expanded polyclonal regulatory T cells, or Tregs) was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of type 1 diabetes mellitus (TID), making it the first known therapeutic candidate for treatment of T1D to receive the designation. CLBS03...
Just one night of wakefulness can lead to alterations in epigenetic and transcriptional profile of core circadian clock genes in key metabolic tissues, which could explain why shift workers are at an increased risk of metabolic morbidities, according to a new study published in the Journal of Clinical Endocrinology & Metabolism. Researchers led by Jonathan...
Bariatric surgery may benefit obese patients with type 1 diabetes (T1D), by leading not only to significant weight loss, but improvements in insulin requirements and glycemic status, according to a study recently published in Diabetes Care. Researchers led by John P. Kirwan, PhD, and Ali Aminian, MD, both of the Cleveland Clinic, point out that...
Just one night of wakefulness can lead to alterations in epigenetic and transcriptional profile of core circadian clock genes in key metabolic tissues, which could explain why shift workers are at an increased risk of metabolic morbidities, according to a new study published in the Journal of Clinical Endocrinology & Metabolism. Researchers led by Jonathan...
